ฤทธิ์ยับยั้งแบคทีเรียและฤทธิ์ยับยั้งเชื้อราของสารที่แยกไดจากจากตนสํามะงา Anti-bacterial and Anti-fungal Activities of Isolated Compounds from *Clerodendrum inerme*

สิริกร ก่ออานันต์¹ พัฒทรา ธีรพิบูลย์เดช²* Sirikorn Kor-arnan¹ Pattara Thiraphibundet^{2*} Received: 13 June 2015; Accepted: 6 September 2015

บทคัดยอ

ประเมินฤทธิ์ยับยั้งแบคทีเรียของสารที่ได้จากใบและรากต้นสำมะงา (วงศ์ผกากรอง) โดยนำพืชตากแห้งมาสกัดด้วยไดคลอโร มีเทน จากนั้นนำกากพืชมาสกัดต่อด้วยเมทานอล นำสิ่งสกัดทั้งหมดมาทดสอบฤทธิ์ยับยั้งแบคทีเรียด้วยวิธี broth microdilution susceptibility พบวาสิ่งสกัดไดคลอโรมีเทนจากใบและรากมีฤทธิ์ยับยั้งแบคทีเรียแกรมบวก (*Staphylococcus aureus* และ *Bacillus subtilis*) และแบคทีเรียแกรมลบ (*Pseudomonas aeruginosa* และ *Escherichia coli*) ไดสูงกวาสิ่งสกัดเมทานอล ่ นำสิ่งสกัดไดคลอโรมีเทนจากใบและรากมาแยกสารออกฤทธิ์ต่อไป ได้สารบริสุทธิ์จำนวน 7 สาร และวิเคราะห์โครงสร้างทางเคมี ดวยขอมูลจากเทคนิคเอ็น เอ็ม อารและแมสสเปกโทรสโกปสารบริสุทธิ์ที่ไดคือ (3β, 22*E*, 24*S*)-stigmasterol-5,22,25-trien-3 ol (1), pectolinarigenin (2), acacetin (3), (3β, 22*E*, 24*S*)-stigmasterol-5,22,25-triene-3-yl-β-D-glucopyranoside (4), stigmasterol (5), lupeol laurate (6) และ betulinic acid (7) สาร 1 มีฤทธิ์ยับยั้งการเจริญของ *S. aureus* สูงที่สุด ขณะที่สาร 1, 6 และ 7 มีฤทธิ์ยับยั้งการเจริญของ *P. aeruginosa* สูง

คําสําคัญ: ตนสํามะงา วงศผกากรอง ฤทธิ์ยับยั้งแบคทีเรีย ฤทธิ์ยับยั้งเชื้อรา

Abstract

Evaluation of anti-microbial activity of phytochemicals from leaves and roots of *Clerodendrum inerme* (Vebenaceae) was conducted. Air dried materials were extracted with CH₂Cl₂ and residues were consequently extracted with MeOH. All extracts were determined for anti-microbial activity by broth microdilution susceptibility testing. The CH₂Cl₂ extracts of leaves and roots exhibited anti-microbial activity toward Gram positive bacteria (*Staphylococcus aureus* and *Bacillus subtilis*) and Gram negative bacteria (*Pseudomonas aeruginosa* and *Escherichia coli*) higher than MeOH extracts. The CH₂Cl₂ extracts of leaves and roots were further isolated for their active compounds. Seven compounds were obtained and further characterized for their chemical structures by NMR and Mass Spectroscopy data as (3β, 22*E*, 24*S*)-stigmasterol-5,22,25-trien-3-ol (1), pectolinarigenin (2), acacetin (3), (3β, 22*E*, 24*S*)-stigmasterol-5,22, 25-triene-3-yl-β-D-glucopyranoside (4), stigmasterol (5), lupeol laurate (6) and betulinic acid (7). Compound 1 exhibited the highest inhibition on *S. aureus* growth whereas compounds 1, 6 and 7 exhibited high inhibition on *P. aeruginosa* growth.

Keywords: *Clerodendrum inerme*, Vebenaceae, anti-bacterial activity, anti-fungal activity

¹ นิสิตปริญญาเอก, สาขาเทคโนโลยีชีวภาพ, ²ผู้ช่วยศาสตราจารย์, ภาควิชาเคมี, คณะวิทยาศาสตร์, จุฬาลงกรณ์มหาวิทยาลัย, กรุงเทพฯ, 10330.

¹ PhD student, Program in Biotechnology, ²Associate Professor, Department of Chemistry, Faculty of Science, Chulalongkorn University, *Bangkok 10330, Thailand.*

^{} Corresponding author. Tel. +662 02-2187624; fax: +662-2187598, 02-2541309. E-mail address: p_tiew@hotmail.com*

Introduction

Clerodendrum inerme L. is a mangrove plant in Verbenaceae family and its common name is scrambling clerodendrum. This plant usually grows along the beach forest in many places such as Western Australia, North East Queensland and the Pacific Islands. The extracts of *C. inerme* have been reported to possess a variety of biological properties such as anti-oxidation $^{1\text{-}2}$, anti-inflammatory $^{3\text{-}5}$, anti-tumor 6 , anti-virus⁷ and growth inhibition of insecticide activities $^{\mathrm{8-9}}$. This extract has also been noted to possess anti-microbial activity. Isoamyl alcoholic extract of *C. inerme* can inhibit *Bacillus subtilis* and *Staphylococcus aureus*10. Moreover, the *C. inerme* extracts have the anti-fungal activity on human pathogen fungi (*Epidermophyton floccosum* and *Trichophyton tonsurans*) and plant pathogen fungi (*Aspergillus flavus* and *Aspergillus niger*) 11. One of the constituents isolated from *C. inerme*, (5*S*,6*R*,8αR)- 5,6,8 α -trimethyl-5-[2-(3-oxo-cyclobutyl)-ethyl] 3,4,4 α , 5,6,7,8,8α-octahydro-naphthalene-1-carboxylic acid methyl ester, showed inhibition on *B. pumilis*, *E. coli* and *A. flavus*12.

 Although *C. inerme* extracts were extensively reported to have anti-microbial potential, it was a rare study that revealed the active constituents responsible for those activities. Thus, in this study, extracts of *C. inerme* were investigated for activity against Gram-positive bacteria (*S. aureus* and *B. subtilis*) and Gram-negative bacteria (*P. aeruginosa* and *E. coli*). The constituents of this plant were isolated and tested for anti-bacterial potency on *S. aureus* and *P. aeruginosa*, including anti-fungal potency on *Candida albicans*.

Materials and Methods

Plant Material Preparation

 Roots and leaves of *C. inerme* were collected in Rayong province, Thailand, on May 2012. A voucher specimen (BCU 013514) has been deposited at the Department of Botany, Faculty of Science, Chulalongkorn University, Thailand.

Extraction and Isolation

 Air dried leaves (3.8 kg) were macerated twice with CH₂Cl₂. After filtration and solvent removal, 57.4 g of CH Cl_2 (L-CH Cl_2) extract was obtained. Leaf residue was subsequently extracted twice with MeOH and 95.2 g of MeOH extract was given after evaporating solvent.

A portion of L-CH₂Cl₂ extract (57.4 g) was fractionated by Si-gel CC and eluted with an increasing polarity of mobile phase *n*-hexane:EtOAc, followed by EtOAc:MeOH, to afford seven fractions (C1-C7). Fraction C2 was further separated by Si-gel CC eluted with *n*-hexane:EtOAc (100:0 \rightarrow 10:90) to afford three fraction C2.1 to C2.3. Fraction C2.1 was purified by Si-gel CC eluting with *n*-hexane:EtOAc (9:1) to obtain compound **1** (1.1 g). Fraction C3 was separated by Si-gel CC eluted with a gradient of *n*-hexane:EtOAc to afford two fractions, and after repeat separation on fraction C3.1 by Si-gel CC eluted with a gradient of *n*-hexane:CH₂Cl₂, compound **2** (46.5 mg) was obtained. Compound **3** (25.0 mg) was gained from fraction C3.2 by Sephadex LH-20 CC eluted with *n*-hexane:CH₂Cl₂:MeOH (7:2.5:0.5), then by Sephadex LH-20 CC eluted with *n*-hexane:CH₂Cl₂ (1:1). Fraction C5 was separated by Si-gel CC eluted with *n*-hexane:EtOAc:MeOH (100:0:0 \rightarrow 0:0:100) to afford two fractions C5.1-C5.2. Fraction C5.1 was separated by Si-gel CC eluted with CH_2Cl_2 :MeOH (9:1) to afford compound **4** (9.0 mg).

The CH₂Cl₂ (R-CH₂Cl₂, 69.9 g) and MeOH (446.5 g) extracts from roots were obtained by extracting the roots of *C. inerme* (4.5 kg) in the same manner as leaves. The R-CH $_2^{\text{Cl}}$ extract (60.5 g) was firstly fractionated by Si-gel CC eluted with *n*-hexane:EtOAc:MeOH (100:0:0 \rightarrow 0:10:90) to afford nine fractions R1-R9. Fraction R2 was separated by Si-gel CC eluted with *n*-hexane:EtOAc $(100:0 \rightarrow 10:90)$ to obtain three fractions R2.1-R2.3. and compound **5** (42 mg) was isolated at solvent ratio of 9:1 from this separation. Fraction R2.2 was separated by Si-gel CC eluted with *n*-hexane:EtOAc (100:0 \rightarrow 10:90), followed by Si-gel CC eluted with *n*-hexane:CH₂Cl₂ (9:1) to yield compound 6 (6 mg). Fraction R4 was separated by Si-gel CC eluted with *n*-hexane:EtOAc (100:0 → 10:90) to afford two fractions R4.1-R4.2. Fraction R4.1 was then purified by Si-gel CC eluted with *n*-hexane:EtOAc (8:2) to yield compound **7** (30 mg).

 (3β, 22*E*, 24*S*)-stigmasterol-5,22,25-trien-3-ol (1): white powder; mp. 121-125°C; ¹H-NMR (CDCl₃,400 MHz) δ 3.54 (1H, *m*, H-3), 5.36 (1H, *brd*, *J*=4.8, H-6),

0.72 (3H, *brs*, H-18), 1.03 (3H, *s*, H-19), 1.04 (3H, *s*, H-21), 5.28 (1H, *dd*, *J*=15.6, 8.0, H-22), 5.21 (1H, *dd*, *J*=15.2, 7.2, H-23), 4.72 (2H, *m*, H-26), 1.67 (3H, *brs*, H-27), 0.86 (3H, *t*, J=7.4, H-27); ¹³C-NMR (CDCl₃, 100 MHz) 37.3 (C-1), 31.9 (C-2), 71.8 (C-3), 42.3 (C-4), 140.8 (C-5), 121.7 (C-6), 31.9 (C-7), 31.7 (C-8), 50.2 (C-9), 36.5 (C-10), 21.1 (C-11), 39.7 (C-12), 42.3 (C-13), 56.9 (C-14), 24.3 (C-15), 28.7 (C-16), 55.9 (C-17), 12.1 (C-18), 19.4 (C-19), 40.1 (C-20), 20.8 (C-21), 137.2 (C-22), 130.1 (C-23), 52.0 (C-24), 148.6 (C-25), 109.5 (C-26), 20.2 (C-27), 25.7 (C-28), 12.1 (C-29).

 Pectolinarigenin (**2**): yellow needle; mp. 210- 211°C; ¹H-NMR (acetone-*d6*, 400 MHz) δ 6.48 (1H, *s*, H-3), 6.53 (1H, *s*, H-8), 7.87 (1H, *d*, *J*=8.8, H-2ʹ, 6ʹ), 6.96 (1H, *d*, *J*=8.8, H-3ʹ, 5ʹ), 3.76 (3H, *s*, 6-OMe), 3.72 (3H, *^s*, 4'-OMe), 13.02 (1H, *s*, 5-OH), 9.31 (1H, *s*, 7-OH) ; 13C-NMR (acetone-*d6*, 100 MHz) 165.0 (C-2), 104.0 (C-3), 183.6 (C-4), 154.0 (C-5), 132.3 (C-6), 157.8 (C-7), 94.8 (C-8), 154.0 (C-9), 105.8 (C-10), 124.4 (C-1ʹ), 115.4 $(C-3', 5')$, 129.1 $(C-2', 6')$, 163.0 $(C-4')$, 60.7 $(6$ -OMe), 56.0 (4ʹ-OMe).

Acacetin (3): yellow needle; mp. 284-289°C; ¹H-NMR (acetone-*d6*, 400 MHz) δ 6.59 (1H, *s*, H-3), 6.17 (1H, *d*, *J*=1.6, H-6), 6.46 (1H, *d*, *J*=1.6, H-8), 7.94 (2H, *d*, *J*=8.8, H-2ʹ, 6ʹ), 7.05 (2H, *d*, *J*=8.8, H-3ʹ,5ʹ), 3.93 (3H, *s*, 4ʹ-OMe), 12.87 (1H, *s*, 5-OH); 13C-NMR (acetone*d6*, 100 MHz) 165.1 (C-2), 104.5 (C-3), 183.1 (C-4), 163.7 (C-5), 99.8 (C-6), 164.8 (C-7), 94.7 (C-8), 158.9 (C-9), 104.6 (C-10), 124.3 (C-1ʹ), 129.1 (C-2ʹ,6ʹ), 115.4 (C-3ʹ,5ʹ), 163.3 (C-4ʹ), 56.0 (C4ʹ-OMe)

 (3β, 22*E*, 24*S*)-Stigmasterol-5,22,25-triene-3-ylβ-D-glucopyranoside (**4**): white powder; mp. 259-261°C;
¹H-NMP (CDCL -400 MHz) δ 3 51 (1H, m, H-3), 5 29 (1H H-NMR (CDCl₃, 400 MHz) δ 3.51 (1H, *m*, H-3), 5.29 (1H, *brd*, *J*=4.4, H-6), 5.12 (1H, *m*, H-22), 5.12 (1H, *m*, H-23), 1.59 (1H, *s*, H-26), 4.63 (1H, *brs*, H-27), 4.35 (1H, *d*, *J*=7.6, H-1ʹ), 3.76 (1H, *m*, H-2ʹ), 3.76 (1H, *m*, H-3ʹ), 3.40 (1H, *m*, H-4'), 3.33 (1H, *m*, H-5'), 3.40 (2H, *m*, H-6'); 13 C-NMR (CDCI₂, 100 MHz) 38.7 (C-1), 29.6 (C-2), 76.3 (C-3), 42.2 (C-4), 140.2 (C-5), 122.1 (C-6), 31.8 (C-7), 36.7 (C-8), 50.1 (C-9), 37.2 (C-10), 21.0 (C-11), 39.6 (C-12), 48.5 (C-13), 56.8 (C-14), 24.2 (C-15), 28.6 (C-16), 55.8 (C-17), 12.0 (C-18), 20.7 (C-19), 40.1 (C-20), 21.0

(C-21), 137.1 (C-22), 130.0 (C-23), 51.9 (C-24), 148.6 (C-25), 19.2 (C-26), 109.4 (C-27), 25.7 (C-28), 12.0 (C-29), 101.0 (C-1ʹ), 73.5 (C-2ʹ), 79.2 (C-3ʹ), 69.9 (C-4ʹ), 75.6 (C-5[']), 61.7 (C-6[']).

Stigmasterol (5): white powder; mp. 147-151^oC;
¹H-NMP (CDCL 400 MHz) δ 1.25 (1H m H-10) 1.99 H-NMR (CDCl3 , 400 MHz) δ 1.25 (1H, *m*, H-1α), 1.99 (1H, *m*, H-1β), 1.52 (1H, *m*, H-2α), 1.83 (1H, *m*, H-2β), 3.52 (1H, *m*, H-3), 2.27 (1H, *m*, H-4α, H-4β), 5.34 (1H, *m*, H-6), 1.60 (1H, *brs*, H-7α), 1.83 (1H, *m*, H-7β), 1.52 (1H, *m*, H-8), 1.03 (1H, *brs*, H-9), 1.52 (1H, *m*, H-11α), 1.60 (1H, *brs*, H-11β), 1.25 (1H, *m*, H-12α), 1.99 (1H, *m*, H-12β), 1.25 (1H, *m*, H-14), 1.03 (1H, *brs*, H-15α), 1.60 (1H, *brs*, H-15β), 1.25 (1H, *m*, H-16α), 1.69 (1H, *m*, H-16β), 1.25 (1H, *m*, H-17), 0.70 (3H, *brs*, H-18), 1.01 (3H, *brs*, H-19), 1.99 (1H, *m*, H-20), 1.01 (3H, *brs*, H-21), 5.15 (1H, *m*, H-22), 5.03 (1H, *dd*, *J*=8.4, 15.2, H-23), 1.52 (1H, *m*, H-24), 1.52 (1H, *m*, H-25), 0.80 (3H, *brs*, H-26), 0.84 (3H, *brs*, H-27), 1.25 (1H, *m*, H-28α), 1.52 (1H, *m*, H-28β), 0.79 (3H, *br*s, H-29); ¹³C-NMR (CDCl₃, 100 MHz) 39.7 (C-1), 31.7 (C-2), 71.8 (C-3), 42.3 (C-4), 140.8 (C-5), 121.7 (C-6), 31.9 (C-7), 31.9 (C-8), 51.2 (C-9), 37.3 (C-10), 21.2 (C-11), 36.5 (C-12), 42.2 (C-13), 56.9 (C-14), 25.4 (C-15), 29.7 (C-16), 56.0 (C-17), 12.0 (C-18), 21.0 (C-19), 40.4 (C-20), 24.4 (C-21), 138.3 (C-22), 129.3 (C-23), 50.2 (C-24), 31.9 (C-25), 21.1 (C-26), 19.4 (C-27), 28.9 (C-28), 12.2 (C-29).

Lupeol laurate (6) : white powder; mp. 214-219 $^{\circ}$ C; ESI-MS *m/z* 631.54 [M+Na]⁺; ¹H-NMR (CDCI₃, 400 MHz) δ 4.39 (1H, *dd*, *J*=5.6, 10.4, H-3), 2.30 (1H, *m*, H-19), 0.79 (3H, *s*, H-23), 0.96 (3H, *s*, H-24), 0.79 (3H, *s*, H-25), 0.76 (3H, *s*, H-26), 0.76 (3H, *s*, H-27), 0.71 (3H, *s*, H-28), 4.61 (1H, *m*, H-29α), 4.57 (1H, *m*, H-29β), 1.61 (3H, *s*, H-30), 2.21 (2H, *t*, *J*=7.6, H-2ʹ), 1.25 (2H, *m*, H-3ʹ-11ʹ), 0.87 (3H, *m*, H-12[']); ¹³C-NMR (CDCI₃, 100 MHz) 39.9 (C-1), 23.6 (C-2), 80.5 (C-3), 38.3 (C-4), 55.3 (C-5), 18.1 (C-6), 34.1 (C-7), 42.9 (C-8), 50.2 (C-9), 37.7 (C-10), 22.5 (C-11), 25.0 (C-12), 37.9 (C-13), 42.7 (C-14), 29.7 (C-15), 34.7 (C-16), 40.7 (C-17), 48.2 (C-18), 47.8 (C-19), 151.0 (C-20), 27.8 (C-21), 37.0 (C-22), 29.5 (C-23), 17.9 (C-24), 16.4 (C-25), 16.0 (C-26), 14.4 (C-27), 15.9 (C-28), 109.2 (C-29), 20.8 (C-30), 173.5 (C-1ʹ), 35.5 (C-2ʹ), 23.0-29.5-(C-3ʹ-C9ʹ), 31.8 (C-10ʹ), 19.1 (C-11ʹ), 13.9 $(C-12')$.

Betulinic acid (7): white powder; mp. 219-239°C;
¹H-NMP (CDCL 400 MHz) δ 0.91 (1H m H-10) 1.69 H-NMR (CDCl3 , 400 MHz) δ 0.91 (1H, *m*, H-1α), 1.69 (1H, *brs*, H-1β), 1.69 (2H, *m*, H-2), 3.00 (1H, *m*, H-3), 0.75 (1H, *m*, H-5), 1.69 (1H, *m*, H-6α), 1.41 (1H, *m*, H-6β), 1.41 (1H, *m*, H-7α), 1.38 (1H, *m*, H-7β), 1.38 (1H, *m*, H-9), 1.38 (1H, *m*, H-11α), 1.25 (1H, *m*, H-11β), 1.25 (1H, *m*, H-12α), 2.23 (1H, *m*, H-12β), 2.23 (1H, *m*, H-13), 1.25 (1H, *m*, H-15α), 2.23 (1H, *m*, H-15β), 1.69 (1H, *m*, H-16α), 1.69 (1H, *brs*, H-18), 3.18 (1H, *m*, H-19), 1.53 (1H, *m*, H-21α), 1.53 (1H, *m*, H-22α), 1.98 (1H, *m*, H-22β), 1.21 (1H, *m*, H-23), 0.94 (3H, *s*, H-24), 0.83 (3H, *s*, H-25), 0.97(3H, *s*, H-26), 0.98 (3H, *s*, H-27), 4.74 (1H, *s*, H-29α), 4.61 (1H, *s*, H-29β), 1.69 (3H, *brs*, H-30); ¹³C-NMR (CDCI₃, 100 MHz) 38.8 (C-1), 27.4 (C-2), 79.0 (C-3), 39.0 (C-4), 55.4 (C-5), 18.3 (C-6), 34.4 (C-7), 40.7 (C-8), 50.6 (C-9), 37.0 (C-10), 20.9 (C-11), 25.5 (C-12), 38.4 (C-13), 42.5 (C-14), 29.7 (C-15), 32.2 (C-16), 56.3 (C-17), 49.3 (C-18), 46.9 (C-19), 150.4 (C-20), 30.6 (C-21), 37.2 (C-22), 28.0 (C-23), 16.1 (C-24), 15.3 (C-25), 16.0 (C-26), 14.7 (C-27), 179.9 (C-28), 109.7 (C-29), 19.4 (C-30).

Antimicrobial Activity Testing

 Bacterial inhibitory activity was tested against Gram positive bacteria (*S. aureus* ATCC25923 and *B.*

subtilis ATCC6633) and Gram negative bacteria (*P. aeruginosa* ATCC27853 and *E. coli* ATCC25922) by broth dilution susceptibility testing according to Clinical and Laboratory Standards Institute (2011)¹³. S. aureus, P. *aeruginosa* and *E. coli* were maintained in ATCC® medium 18 (trypticase soy medium) at 37°C, *B. subtilis* was in ATCC $^{\circledR}$ medium 44 (brain heart infusion medium) at 30°C and *C. albicans* was in ATCC[®] medium 200 (YM medium) at 24-26°C in ATCC $^\circledR$ medium 200 (YM medium). A single colony of bacteria was isolated by cross streaking on medium and incubated at 37° C for 24 hr. It was further cultured in Müller-Hinton broth and the turbidity was adiusted with Mcfarland standard No. 0.5 (1×10 8 CFU/mL). Culture suspension 100 μL was mixed with the serial dilution of extract suspension in Müller-Hinton broth at the concentration ranging from 50-300 μg/mL in sterile microplate. They were then incubated at 37° C for 16-18 hr. Minimum inhibitory concentration (MIC) was defined as the lowest concentrations of samples that resulted in no bacterial growth. In this study, clavulanic acid was used as a standard and all experiments were done in triplicate. The isolated compounds (5-50 μg/mL) were tested using the same method as mentioned and amphotericin B was used as a standard for antifungul activity.

Figure 1 Chemical structures of the constituents isolated from *C. inerme*

Results and Discussions

The CH₂Cl₂ and MeOH extracts of *C. inerme* were evaluated the antibacterial activity on Gram positive bacteria (*S. aureus* and *B. subtilis*) and Gram negative bacteria (*P. aeruginosa* and *E. coli*) at a range of concentration of 50-300 μg/mL (Table 1). All extracts have the potential to inhibit bacteria with the concentration of 50 and 100 μg/mL. This result was found to agree with a previous report in which the methanolic extract of *C. inerme* inhibited these four bacteria¹⁴. However, in this study the $CH_2^{\bullet}Cl_2^{\bullet}$ extract from leaves and roots were subjected to fractionation to obtain bioactive compounds. Phytochemicals separation of *C. inerme* led to the isolation of seven compounds. The chemical structures of all isolated compounds were identified based on the NMR data and compared to those in the previous reports. The names of these isolated compounds were (3β, 22*E*, 24*S*)-stigmasterol-5,22,25-triene-3-ol (**1**) 15, pectolinarigenin (**2**) 16, acacetin (**3**) **¹⁷**, and (3β, 22*E*, 24*S*)-stigmasterol-5,22,25 trien-3-yl-D-glucopyranoside (**4**) 18, stigmasterol (**5**) 19, lupeol laurate (**6**) 20 and betulinic acid (**7**) 21. Their chemical structures were shown in Figure. 1. Compounds **2**, **4** and **6** were reported for the first time from this species.

Table 1 Minimum inhibitory concentration (MIC) of extracts from *C. inerme* against *S. aureus*, *B. subtilis, P. aeruginosa* and *E. coli*

 These isolated compounds were tested for anti-microbial activity by microdilution broth susceptibility method at a range of concentration of 5-50 μg/mL (Table 2).

Table 2 Minimum inhibitory concentration (MIC) of phytochemical compounds from *C. inerme* against *S. aureus, P. aeruginosa* and *C. albicans*

Com		MIC (μ g/mL) \pm SE			
pound	Name	Part	S. aureus	P. aeruginosa	C. albicans
		of Plant	ATCC25923	ATCC27853	ATCC10231
1	$(3\beta, 22E, 24S)$ -stigmasta-5,22,25-	Leaves	20.0 ± 0.00	45.0 ± 0.00	45.0 ± 0.00
	trien-3-ol				
2	Pectolinarigenin	Leaves	45.0 ± 0.00	$> 50.0 \pm 0.00$	40.0 ± 0.00
3	Acacetin	Leaves	41.7 ± 0.96	$> 50.0 \pm 0.00$	36.7 ± 0.96
4	$(3\beta, 22E, 24S)$ -stigmasta-5,22,25-	Leaves	$> 50.0 \pm 0.00$	$> 50.0 \pm 0.00$	$> 50.0 \pm 3.84$
	triene-3-yl- β -D-glucopyranoside				
5	Stigmasterol	Roots	33.3 ± 0.96	46.7 ± 0.96	$> 50.0 \pm 0.00$
6	Lupeol laurate	Roots	$> 50.0 \pm 0.00$	45.0 ± 0.00	$> 50.0 \pm 0.00$
7	Betulinic acid	Roots	45.0 ± 0.00	45.0 ± 0.00	$> 50.0 \pm 0.00$
8	Clavulanic acid		$1.35 \pm 0.0.96$	2.45 ± 0.00	
9	Amphotericin B				2.51 ± 0.00

Compound **1** showed the highest inhibition on *S. aureus* growth with the MIC value of 20 μg/mL while compounds **1**, **6** and **7** showed the highest inhibition on *P. aeruginosa* with the same MIC value (45 μg/mL). The best *C. albicans* inhibitor was compound **3**. This study is the first report of compounds **1** and **6** activities against *S. aureus* and *P. aeruginosa*. The glucoside moiety on compound **1** was found to significantly reduce the antibacterial and also anti-fungal activities (compound **1** *vs.* compound **4**). This phenomenon was previously found in the saponin skeleton reported by Avato *et al*. 22 Flavanoids **2** and **3** exerted the inhibition on *S. aureus* and *C. albicans* which might be related to the hydroxyl groups at C-5 and C-7 of ring A^{23} .

Conclusion

The *C. inerme* extracts were shown to possess antibacterial activity with the MIC values of 50-100 μg/mL. The isolation led to obtain 4 compounds from leaf extract and 3 compounds from root extract. Compound **1** showed inhibition on *S. aureus*, *P. aeruginosa* and *C. albicans* with the concentration lower than 50 μg/mL while compound **4** had no inhibitory potency at this concentration against three microbial isolates. Although the structure activity relationship of the isolated compounds could not be determined, this study confirmed their antimicrobial activity.

Acknowlegements

 The authors thank the National Science and Technology Development Agency (NSTDA) and the 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) for financial support.

References

- 1. Khan SA, Rasool N, Riaz M, Nadeem R, Rashid U, Rizwan K, Zubair M, Bukhari IH, Gulzar T. Evaluation of antioxidant and cytotoxicity studies of *Clerodendrum inerme*. Asian Journal of Chemistry 2013;25(13):7457- 7462.
- 2. Masuda T, Yonemori S, Oyama Y, Takeda Y, Tanaka T, Andoh T, Shinohara A, Nakata M.

Evaluation of the antioxidant activity of environmental plants: activity of the leaf extracts from seashore plants. Journal of Agricultural and Food Chemistry 1999; 47(4):1749-1754.

- 3. Srisook K, Srisook E, Nachaiyo W, Chan-In M, Thongbai J, Wongyoo K, Chawsuanthong S, Wannasri K, Intasuwan S, Watcharanawee K. Bioassay-guided isolation and mechanistic action of anti-inflammatory agents from *Clerodendrum inerme* leaves. Journal of Ethnopharmacology 2015;165: 94-102.
- 4. Ibrahim SRM, Alshali KZ, Fouad MA, Elkhayat ES, Al Haidari RA, Mohamed GA. Chemical constituents and biological investigations of the aerial parts of Egyptian *Clerodendrum inerm*e. Bulletin of Faculty of Pharmacy, Chairo University 2014;52:165-170.
- 5. Somasundaram S, Sadique J. The role of mitochondrial calcium transport during Inflammation and the effect of anti-inflammatory drugs. Biochemical Medicine and Metabolic Biology 1986;36(12):220-230.
- 6. Uddin SJ, Grice ID, Tiralongo E. Cytotoxic effects of Bangladeshi medicinal plant extracts. Evidence*-*Based Complementary and Alternative Medicine 2011;25:1-7.
- 7. Prasad HP, Shankar UAC, Kumar BH, Shetty SH, Prakash HS. Management of bean common mosaic virus strain blackeye cowpea mosaic (BCMV-BICM) in cowpea using plant extracts. Archives of Phytopathology and Plant Protection 2007*;*40:139-147.
- 8. Kovendan K, Murugan K. Effect of medicinal plants on the mosquito vectors from the different agroclimatic regions of Tamil Nadu, India. Advances in Environmental Biology 2011;5(2):335-344.
- 9. Yankanchi SR, Gadache AH. Grain protectant efficacy of certain plant extracts against rice weevi, *Sitophilus oryzae* L. (Coleoptera: Curculionidae). Journal of Biopesticides 2010;3(2):511-513.
- 10. Prasad MP, Sushant S, Chikkaswamy BK. Phytochemical analysis, antioxidant potential, antibacterial activity and molecular characterization of *Clerodendrum* species. International Journal of Molecular Biology 2012;3:71-76.
- 11. Anitha R, Kannan P. Antifungal activity of *Clerodendrum inerme* L. and *Clerodendrum phlomidis* L. Turkish Journal of Biology 2006;30:139-142.
- 12. Murthy YLN, Nageswar PE, Viswanath IVK, Lakshmi BS. Phytochemical analysis and screening for antimicrobial activity of *Clerodendrum inerme* I. Gaertn : a mangrove plant. Journal of Pharmacy and Chemistry 2009;3(2):51-56.
- 13. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing: Twenty-first Informational supplement M100-S21CL-SI. Wayne(PA); 2011.
- 14. Chahal JK, Sarin R, Malwal M. Efficacy of *Clerodendrum inerme* (garden quinine) against some human pathogenic strains. International Journal of Pharma and Bio Sciences 2010;1(4):219-223.
- 15. Leitao SG, Kaplan MAC, Monache FD, Akihisa T, Tamura T. Sterols and glucosides from two *Aegiphila* species. Phytochemistry 1992;31(8): 2813-2817.
- 16. Lu M, Kong Q, Xu X, Lu H, Lu Z, Yu W, Zuo B, Su J, Guo R. Pectolinarigenin - a flavonoid compound from *Cirsium japonicum* with potential anti-proliferation activity in MCF-7 breast cancer cell. Tropical Journal of Pharmaceutical Research 2014*;*13(2):225-228.
- 17. Gomes RA, Ramirez RRA, Maciel JKS, Agra MF, Souza MFV, Falcao-Silva VS, Siqueira-Junior JP. Phenolic compounds from *Sidastrum micranthum* (A.

St.-Hil.) fryxell and evaluation of acacetin and 7,4'- Di-O-methylisoscutellarein as motulator of bacterial drug resistance. Quimica Nova 2011;34:1385-1388.

- 18. Chaves MH, Roque NF, Ayres MCC. Steroids and flavonoids of Porcelia macrocarpa. Journal of the Brazilian Chemical Society*.* 2005*;*15(4):608-613.
- 19. Koay YC, Wong KC, Osman H, Eldeen I, Asmawi MZ. Chemical constituents and biological activities of *Strobilanthes crispus* L. Records of Natural Products 2013*;*7(1):59-64.
- 20. Sobrinho DC, Hauptli MB, Appolinario EV, Kollenz CLM, De Carvalho MG, Braz-Filho R. Triterpenoids isolated from *Parahancornia amapa*. Journal of the Brazilian Chemical Society 1991;2(1):15-20.
- 21. Peng C, Bodenhausen G, Qiu S, Fong HHS, Farnsworth NR, Yuan S, Zheng C. Computer-assisted structure elucidation: application of CISOC-SES to the resonance assignment and structure generation of betulinic acid. Magnetic resonance in Chemistry 1998;36:267-278.
- 22. Avato P, Bucci R, Tava A, Vitali C, Rosato A, Bialy Z, Jurzysta M. Antimicrobial activity of saponins from *Medicago* sp.: Structure-activity relationship. Phytotherapy Research 2006;20:454-457.
- 23. Wu T, He M, Zang X, Zhou Y, Qiu T, Pan S, Xu X. A structure–activity relationship study of flavonoids as inhibitors of *E. coli* by membrane interaction effect. Biochimica et Biophysica Acta 2013;1828:2751-2756.